Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
Identifieur interne : 000180 ( Istex/Curation ); précédent : 000179; suivant : 000181Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
Auteurs : Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill [Canada] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-11.
English descriptors
Abstract
L‐Dopa‐induced dyskinesia in patients with Parkinson's disease can be alleviated by amantadine, an antagonist at N‐methyl‐D‐aspartate glutamate receptors. The antiepileptic drug topiramate, which blocks α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptors, has also been shown to reduce dyskinesia. The purpose of this study was to examine the behavioral pharmacology of topiramate alone and in combination with amantadine in animal models of PD and L‐dopa‐induced dyskinesia. The effects of topiramate (5–20 mg/kg) and amantadine (5–20 mg/kg) on abnormal involuntary movements (the rat homologue of dyskinesia) and Rotarod performance were assessed alone and in combination in the 6‐hydroxydopamine‐lesioned rat following chronic L‐dopa treatment. Dyskinesia, parkinsonian disability, and “on‐time” were assessed in the MPTP‐lesioned nonhuman primate following administration of topiramate (5–20 mg/kg) and amantadine (0.1–1.0 mg/kg) alone and in combination. Topiramate and amantadine dose‐dependently reduced dyskinesia in the 6‐hydroxydopamine‐lesioned rat, whereas topiramate reduced Rotarod performance; there was no effect on parkinsonian disability in the MPTP‐lesioned nonhuman primate, in which both drugs reduced dyskinesia. Topiramate and amantadine exhibited differential antidyskinetic effects on dyskinesia elicited by the dopamine D1 receptor agonist SKF 38393 (2 mg/kg). Subthreshold doses of both drugs in combination had a synergistic effect on dyskinesia in the 6‐hydroxydopamine‐lesioned rat, with no worsening of motor performance; this effect was confirmed in the MPTP‐lesioned nonhuman primate, with a selective reduction in “bad on‐time.” These data confirm the antidyskinetic potential of topiramate and suggest that combination with low‐dose amantadine may allow better reduction of dyskinesia with no adverse motor effects. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23867
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000180
Links to Exploration step
ISTEX:71D933598B65DAEC1D4FC362CD0E10BCCBB7BA8ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease</title>
<author><name sortKey="Kobylecki, Christopher" sort="Kobylecki, Christopher" uniqKey="Kobylecki C" first="Christopher" last="Kobylecki">Christopher Kobylecki</name>
<affiliation wicri:level="1"><mods:affiliation>Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Faculty of Life Sciences, University of Manchester, Manchester</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Faculty of Medical and Human Sciences, University of Manchester, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Faculty of Medical and Human Sciences, University of Manchester, Manchester</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Greater Manchester Neurosciences Centre, Salford, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, Greater Manchester Neurosciences Centre, Salford</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name>
<affiliation wicri:level="1"><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<affiliation wicri:level="1"><mods:affiliation>Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Faculty of Life Sciences, University of Manchester, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name>
<affiliation wicri:level="1"><mods:affiliation>Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Faculty of Life Sciences, University of Manchester, Manchester</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:71D933598B65DAEC1D4FC362CD0E10BCCBB7BA8A</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23867</idno>
<idno type="url">https://api.istex.fr/document/71D933598B65DAEC1D4FC362CD0E10BCCBB7BA8A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000180</idno>
<idno type="wicri:Area/Istex/Curation">000180</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease</title>
<author><name sortKey="Kobylecki, Christopher" sort="Kobylecki, Christopher" uniqKey="Kobylecki C" first="Christopher" last="Kobylecki">Christopher Kobylecki</name>
<affiliation wicri:level="1"><mods:affiliation>Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Faculty of Life Sciences, University of Manchester, Manchester</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Faculty of Medical and Human Sciences, University of Manchester, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Faculty of Medical and Human Sciences, University of Manchester, Manchester</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Greater Manchester Neurosciences Centre, Salford, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, Greater Manchester Neurosciences Centre, Salford</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name>
<affiliation wicri:level="1"><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<affiliation wicri:level="1"><mods:affiliation>Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Faculty of Life Sciences, University of Manchester, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name>
<affiliation wicri:level="1"><mods:affiliation>Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Faculty of Life Sciences, University of Manchester, Manchester</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-11">2011-11</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">13</biblScope>
<biblScope unit="page" from="2354">2354</biblScope>
<biblScope unit="page" to="2363">2363</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">71D933598B65DAEC1D4FC362CD0E10BCCBB7BA8A</idno>
<idno type="DOI">10.1002/mds.23867</idno>
<idno type="ArticleID">MDS23867</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>6‐OHDA‐lesioned rat</term>
<term>MPTP‐lesioned primate</term>
<term>amantadine</term>
<term>dyskinesia</term>
<term>topiramate</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">L‐Dopa‐induced dyskinesia in patients with Parkinson's disease can be alleviated by amantadine, an antagonist at N‐methyl‐D‐aspartate glutamate receptors. The antiepileptic drug topiramate, which blocks α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptors, has also been shown to reduce dyskinesia. The purpose of this study was to examine the behavioral pharmacology of topiramate alone and in combination with amantadine in animal models of PD and L‐dopa‐induced dyskinesia. The effects of topiramate (5–20 mg/kg) and amantadine (5–20 mg/kg) on abnormal involuntary movements (the rat homologue of dyskinesia) and Rotarod performance were assessed alone and in combination in the 6‐hydroxydopamine‐lesioned rat following chronic L‐dopa treatment. Dyskinesia, parkinsonian disability, and “on‐time” were assessed in the MPTP‐lesioned nonhuman primate following administration of topiramate (5–20 mg/kg) and amantadine (0.1–1.0 mg/kg) alone and in combination. Topiramate and amantadine dose‐dependently reduced dyskinesia in the 6‐hydroxydopamine‐lesioned rat, whereas topiramate reduced Rotarod performance; there was no effect on parkinsonian disability in the MPTP‐lesioned nonhuman primate, in which both drugs reduced dyskinesia. Topiramate and amantadine exhibited differential antidyskinetic effects on dyskinesia elicited by the dopamine D1 receptor agonist SKF 38393 (2 mg/kg). Subthreshold doses of both drugs in combination had a synergistic effect on dyskinesia in the 6‐hydroxydopamine‐lesioned rat, with no worsening of motor performance; this effect was confirmed in the MPTP‐lesioned nonhuman primate, with a selective reduction in “bad on‐time.” These data confirm the antidyskinetic potential of topiramate and suggest that combination with low‐dose amantadine may allow better reduction of dyskinesia with no adverse motor effects. © 2011 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000180 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000180 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:71D933598B65DAEC1D4FC362CD0E10BCCBB7BA8A |texte= Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |